Loading stock data…
$1.31-0.00 (-0.38%)
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
NanoViricides, Inc. in the Healthcare sector is trading at $1.31 with a market capitalization of $45M. Wall Street consensus targets $6.00 (2 analysts), implying a +356.3% move over the next 12 months. The stock is currently 41% below its 52-week high of $2.23, remaining 2.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.03M↑ | -$2.23M↓ | -$1.80M↑ | -$2.12M↑ | -$2.25M |
| Net Income | -$1.99M↑ | -$2.22M↓ | -$1.79M↑ | -$2.10M↑ | -$2.22M |
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications...